The antibody which was identified from an HIV-infected person neutralised 98 percent of HIV isolates tested.
The scientists tracked how N6 had evolved over time in order to understand its development and its ability to potently neutralise nearly all HIV strains.
The research which was led by Mark Connors, M.D of NIH’s National Institute of Allergy and Infectious Diseases (NIAID), was able to identify the neutralising antibody against HIV.
Identifying neutralising antibodies has been difficult because the virus rapidly changes its surface proteins which have hindered the immune system from recognising it.
Scientists were able to discover an antibody called VRC01 in 2010 which was able to stop about 90 per cent of HIV strains from infecting human cells.
However, the recently discovered antibody may procure stronger treatment benefits and may safely prevent HIV infection in humans.
“Findings from the current study showed that N6 evolved a unique mode of binding that depends less on a variable area of the HIV envelope known as the V5 region and focuses more on conserved regions, which change relatively little among HIV strains,” said NIAID.
“This allows N6 to tolerate changes in the HIV envelope, including the attachment of sugars in the V5 region, a major mechanism by which HIV develops resistance to other VRC01-class antibodies.”